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Abbreviations 
% body fat   percentage of body fat 
%    percentage 
°C     degree Celsius 
µm    micrometers 
µmol/kg/min   micromol per kilogram per minute 
ABSI    A Body Shape Index 
ADAMTS9 a disintegrin-like and  metallopeptidase with thrombospondin 
type 1 motif 9 
adj    adjusted 
AGPAT2   lysophosphatidic acid acyltransferase-β 
AKT1    AKT serine/threonine kinase 1 
AT    adipose tissue 
ATF-4    activating transcription factor 4 
ATXN1 ataxin 1 
AU    arbitrary unit 
BMI    body mass index 
BMP2    bone morphogenetic protein 2 
Bp    base pairs 
BSCL2    seipin 
C/EBPA   CCAAT/ enhancer binding protein alpha 
C/EBPB   CCAAT/ enhancer binding protein beta 
C/EBPγ   CCAAT/enhancer binding protein gamma 
CAV1    caveolin 1 
CCL5    C-C motif chemokine ligand 5 
CGL    congenital generalized lipodystrophy 
cm    centimeter 
cm²    square centimeter 
CO2 carbon dioxide 
CPEB4 cytoplasmic polyadenylation element binding protein 4 
CT    computerized tomography 
DEPICT Data-driven Expression Prioritized Integration for Complex 
Traits 
DEXA    dual energy X-ray absorptiometry 
DMEM   Dulbecco´s Modified Eagle´s Medium 
DNA    desoxy ribonucleic acid 
DNM3-PIGC dynamin 3-phosphatidylinositol glycan anchor biosynthesis 
class C 
Epi    epididymal 
eQTL expression quantitative trait loci 
et al. et alii, et aliae, et alia 
EWAS epigenomic wide association study 
FBS    fetal bovine serum 
  Abbreviations 
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FD    fat distribution 
FFA    free fatty acids 
FML    familial multiple lipomatosis 
FPG    fasting plasma glucose 
FTO fat mass and obesity associated  
GRAIL Gene Relationships Among Implicated Loci 
GRB14-COBLL1 growth factor receptor bound protein 14 - cordon-bleu WH2 
repeat protein like 1 
GWAS   genome wide associations studies 
h    hour 
HAART   highly active antiretroviral therapy 
HbA1c   glycohemoglobin 
HDL high density lipoprotein 
HIF3A    hypoxia inducible factor 3 alpha 
HIV    human immunodeficiency virus  
HMGA2   high mobility group AT-hook 2 
HOXC13 homeobox C13 
IBMX    3-isobutyl-1-methylxanthine 
Ing    inguinal 
IR insulin resistance 
IRX3/5 iriquois homeobox 3/5 
ITPR2-SSPN inositol 1,4,5-trisphosphate receptor type 2- sarcospan 
kDa kilo dalton 
kg/m²    kilogram per square meters 
KLF13 kruppel like factor 13 
LD linkage disequilibrium 
LDL low density lipoprotein 
LHFP    LHFPL tetraspan subfamily member 6 
LHX2 LIM homeobox 2 
LMNA    lamin A/C 
LPP LIM domain containing preferred translocation partner in 
lipoma 
LY86    lymphocyte antigen 86 
LYPLAL1 lysophospholipase like 1 
m meter 
MAGENTA Meta-Analysis Gene-set Enrichment of variaNT Associations 
Mb megabase 
MCR4    melanocortin 4 receptor 
mM    milli Molar 
mmol/l   millimol per liter 
MRI    magnetic resonance imaging 
mRNA messenger Ribonucleic Acid 
ms    milliseconds 
NCBI National Center for Biotechnology Information 
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NCEP-ATP III The third Report of the National Cholesterol Education Program 
of the Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults 
NFE2L3   nuclear factor, erythroid 2 like 3 
NISCH-STAB1 nischarin- stabilin 1 
nM    nanomolar 
OGTT    oral glucose tolerance test 
p p-value 
PBS    phosphate buffered saline 
pmol/l    picomol per liter 
PPARG   peroxisome proliferator activated receptor gamma  
PTEN phosphatase and tensin 
PTRF    caveolae associated protein 1 
QTL quantitative trait locus 
R    correlation coefficient 
RANTES   synonym for CCL5 (C-C motif chemokine ligand 5) 
REPIN1   replication initiator 1 
RREB1 ras responsive element binding protein 1 
RSPO3   R-spondin 3 
ScAT    subcutaneous adipose tissue 
SHBG    sex-hormone binding globulin 
siRNA    small interfering ribonucleic acid 
SNP    single nucleotide polymorphism 
T2D    type 2 diabetes 
T3    triiodthyronine 
TBOX15-WARS  T-box 15- tryptophanyl-tRNA synthetase 
TG    triglyceride 
TRIB2 tribbles pseudokinase 2 
unadj.    unadjusted 
V    volt 
VAT    visceral adipose tissue 
VEGFA   vascular endothelial growth factor A 
WC    waist circumference 
WCadjBMI   waist circumference adjusted for body mass index 
WHO    world health organisation  
WHR    waist-to-hip-ratio 
WHRadjBMI   waist-to-hip-ratio adjusted for body mass index 
ZNRF3-KREMEN1 zinc and ring finger 3- kringle containing transmembrane 
protein 1 
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Chapter 1 Introduction 
1.1. Obesity and fat distribution 
Obesity is a worldwide health problem with more than 650 million obese adults reported in 
2016 1. According to the World Health Organization (WHO) obesity is an “abnormal or 
excessive fat accumulation that may impair health” 1. The most common measurement of 
obesity is the body mass index (BMI), whereby obesity is defined as a BMI>30 kg/m². One 
major cause of obesity is the dysbalance between energy intake and expenditure, resulting in 
storage of triglycerides (TG) in adipose tissue (AT). It is well acknowledged that both genetic 
and environmental factors play a role in the etiology of this complex heterogeneous disease. 
There is a strong evidence that obesity is associated with increased individual risk for 
comorbidities like type 2 diabetes (T2D), fatty liver disease, hypertension or cardiovascular 
disease 2. Nevertheless, obesity alone does not necessarily lead to these comorbidities. In the 
last two decades it has been shown that the AT is not only a passive fuel reservoir, but also an 
endocrine organ distributed to different sites of the body 3. Peiris 4 and Björntorp 5 could show 
very early that anthropometric parameters correlate with fat distribution (FD) and that the body 
fat is mainly distributed in two fat depots, subcutaneous and visceral AT (ScAT and VAT). If 
the fat is preferentially stored in VAT (android/“apple” body shape 6), subjects with obesity are 
more fragile for complications such as metabolic and cardiovascular diseases (Figure 1). The 
regional AT distribution appears to be the major mediator between obesity and metabolic 
disorders in glucose and lipid metabolism 7. VAT is represented by mesenteric, gonadal, 
epicardial, retroperitoneal, omental and peri-renal fat pads, while ScAT includes abdominal, 
gluteal and femoral depots. These fat depots differ in their structure and function, which could, 
at least partially, explain the higher risk for metabolic and cardiovascular diseases in subjects 
with excess of VAT 3 (Figure 1). 
The AT is constituted of a large number of adipocytes, connective tissue matrix, vascular and 
neural tissue and other non-adipocyte cells. These non-adipocyte cells are represented by 
inflammatory cells like macrophages, immune cells, fibroblasts and preadipocytes 8. The 
adipocytes are the chief cellular units in AT, serving as the main storage of energy. Smaller 
adipocytes absorb free fatty acids (FFA) and TG and perform as a buffer in the postprandial 
time. If the adipocytes become larger they are likely to be more dysfunctional, in particular 
insulin-resistant and hyperlipolytic 9. The VAT contains more of the large adipocytes 10, shows 
increased vascularization and is more innervated compared to the ScAT 8. The fact that insulin 
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resistance is positively associated with the amount of VAT can be considered as an important 
link between obesity and its metabolic sequelae such as cardiovascular diseases 9. The AT is a 
very dynamic organ - the lipid excess accrues in increased adipocyte size (hypertrophy) and/or 
increased number of adipocytes (hyperplasia) and leads to expansion of ScAT and VAT 11.  
1.1.1. Measurement of fat distribution 
Anthropometric parameters like waist circumference (WC) and waist-to-hip ratio (WHR) are 
commonly used measures of FD. WC of 102 cm in men and 88 cm in women is considered as 
a cutoff for a risk of the metabolic syndrome according to the third Report of the National 
Cholesterol Education Program of the Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults (NCEP-ATP III) 12. The WHR is calculated with the WC 
measured by the approximate midpoint between the lower margin of the last palpable rib and 
the top of the iliac crest, and the widest circumference measured at the hips and the buttocks 
(hip) 13.  
A more precise assessment of body fat composition is provided by imaging techniques such as 
dual energy X-ray absorptiometry (DEXA), computerized tomography (CT) or magnetic 
resonance imaging (MRI) 14. With CT or MRI scans the visceral and subcutaneous fat area are 
measured at the level of L4 - L5 or the umbilicus 15, which allow calculating the ratio of VAT 
to ScAT. This ratio has been reported to correlate with impaired lipid and glucose metabolism 
in subjects with obesity and allows further categorizing individuals with obesity in visceral 
obese (>0.4) and subcutaneous obese (<0.4) 16. In 2012, Krakauer et al. calculated A Body 
Shape Index (ABSI), which is defined by ABSI = WC (m) / [BMI2/3 x height (m) 1/2] and is 
reported to be a more adequate index for the evidence of chronic diseases like cardiovascular 
diseases 17. However, its use in the clinical practice is limited due to the lack of a robustly 
defined physiologic cutoff 18. 
1.1.2. Which factors determine fat distribution? 
Besides genetic factors, sex, age, total body fat content and energy balance are influencing 
factors for the accumulation of VAT (Figure 1). VAT increases with age independently of BMI 
in both genders 19. A close linear correlation was reported between age and the volume of VAT 
in men 20. This is also present in women, but weaker in the premenopausal condition while 
becoming stronger in postmenopausal women 20. This gender-related difference in VAT 
accumulation could be one important factor to explain the gender-specific risk of cardiovascular 
events 21. It has been shown that the sexual hormones play a role in the fat accumulation. The 
visceral fat mass in men is negatively correlated with the sex-hormone binding globulin 
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(SHBG) and testosterone 22, whereas SHBG is further associated with increased levels of 
circulating insulin 23. In postmenopausal women, the decreasing estrogen and/or increasing 
androgens may result in a fat redistribution from the periphery to the intra-abdominal 
compartments 24. In addition, changes in endocrine pathways can lead to a shifting from 
peripheral to central parts of the body, for example in patients with the Cushing´s syndrome 
manifesting increased cortisol clearance 19.  
High energy intake may be associated with an accumulation of VAT due to a dysfunctional AT 
unable to expand through hyperplasia 25,26, but the overall interrelation between energy intake 
and the accumulation of fat at particular sites in the body seems to be more complex. Bouchard 
et al. showed in an experiment with hyper-energetic nutrition in monozygotic twins a 
correlation of energy intake and ScAT, while the variation in VAT was less than 10 % 27. But 
it has also been reported, that during weight loss, people are more prone to loose VAT than 
ScAT and an explanation could be the higher metabolic activity of VAT compared with ScAT 
15. In line with this, a short-term dietary fructose restriction in children with obesity showed a 
decrease of VAT and liver fat 28. 
In addition, studies suggest that environmental and dietary factors may affect FD directly 
(Figure 1). Ronn et al. reported in rodents, that bisphenol A (used as part of food packaging) 
may cause higher liver fat content 29. Furthermore, the exposure to urban air pollution is 
responsible for oxidative stress, which is associated with measures of adiposity 30,31.  Air 
pollution promotes insulin resistance and visceral inflammation in a mouse model 32. Factors 
like psychosocial and socioeconomic handicaps, depression and anxiety, alcohol and also 
smoking activate the respective stress centers. This may result in ´stress-eating´. Other 
consequences could bethe activation of the sympathetic nervous system as suggested by 
associations between adrenal hormones and obesity and centralization of body fat 33.  
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Figure 1. Schema for factors, which influence body fat distribution and approaches to identify novel 
candidate genes.  
 
1.2. Genetics of obesity and fat distribution 
Numerous studies strongly implicate that genetic components play an important role in the 
development of obesity 34. However, there is good evidence that not only obesity itself, but also 
fat distribution is controlled by genetic factors 35 (Figure 1). After accounting for BMI, WHR 
is heritable with estimates ranging from 22-61 % 36–38. In a very early work, Bouchard et al. 
could show that in identical twins the within-pair similarity was particular evident in regard to 
changes in FD and amount of visceral abdominal fat with significantly more variance among 
pairs than within pairs 27. Another example is the Quebec Family Study, which show 56 % 
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estimated heritability for VAT and only 42 % heritability was estimated for ScAT 39. This study 
indicated that the genetic influence on familial aggregation has a greater effect on VAT than on 
ScAT, independent of the total body fat. Malis et al. supported these findings with a study in 
young and elderly Danish twins. They reported heritability estimates for WHR to 72-80 %, total 
fat to 83-86 % and trunk and lower body fat to 81-85 % 40. Finally, Schousboe et al. estimated 
the heritability of total body fat percentage among twins in the range of 59-63 % 41.  
The genetic influence on FD is also seen in syndromes like lipodystrophy. Lipodystrophy 
includes a heterogeneous group of disorders characterized by partial or complete absence of AT 
42. The different forms can be divided in acquired or inherited lipodystrophy. The severity of 
the disease depends on the degree of fat loss. Two major factors causing metabolic dysfunction 
are believed to be dyslipidemia and alteration of the adipokine profile 43. 
The congenital generalized lipodystrophy (CGL) is an autosomal recessive disorder, which is 
caused by mutations in different genes, all of which are involved in lipid droplet formation and 
triglyceride synthesis 43, namely lysophosphatidic acid acyltransferase-β (AGPAT2), seipin 
(BSCL2), caveolin 1 (CAV1) and caveolae associated protein 1 (PTRF) 44–47. AGPAT2 was 
reported to affect the adipocyte differentiation via AKT serine/threonine kinase 1 (AKT1) and 
peroxisome proliferator activated receptor gamma (PPARG) 48. The other genes, BSCL2, CAV1 
and PTFR, are mainly concerned in vesicle trafficking and affect the formation or maturation 
of lipid droplets 48. CGL is characterized by a near-complete lack of body fat from birth or from 
very young age and these patients have nearly no metabolically active storage fat, but 
mechanical fat (e.g. orbits, palms and soles) is still existing 48,49. During the childhood the 
patients develop symptoms of metabolic syndrome like dyslipidemia, triglyceride accumulation 
50 and hyperinsulinemia or T2D 51.  
Some of these symptoms are observed in both forms of partial lipodystrophy, the familial partial 
lipodystrophy (inherited) and the most common acquired form, where patients with human 
immunodeficiency virus (HIV) receive highly active antiretroviral therapy (HAART) with 
protease inhibitors 52. These protease inhibitors decrease the levels of major transcriptions 
factors, which regulate adipocyte differentiation and function like CCAAT/enhancer binding 
protein gamma (C/EBPγ) and PPARγ 43. Altered PPARγ activity is also shown in patients with 
familial partial lipodystrophy type 3 caused by mutations in PPARγ 53. The familial partial 
lipodystrophy of the Dunnigan type is attributed to mutations in the lamin A/C gene (LMNA) 
54. This type is exhibited by gradual loss of ScAT in the trunk and extremities, but the face and 
neck are not affected 55. The mutations in LMNA affect the nuclear stability and may result in 
premature cell death of adipocytes 56. The loss of the ScAT occurs at the time of puberty and 
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complications such as insulin resistance and increased levels of lipid parameters can develop 
57. It was also shown that variants in LMNA were associated with metabolic parameters related 
to T2D and obesity 58,59, and so it seems that this gene might be involved in the dysfunction of 
VAT.  
Another syndrome with an altered FD is the autosomal-dominant inherited disease familial 
multiple lipomatosis (FML) 60 with patients manifesting many painless encapsulated 
subcutaneous lipomas over the torso and limbs. High mobility group AT-hook 2 (HMGA2) was 
reported to be a possible candidate gene, because it was discovered on a region on chromosome 
12q13-15, which is linked to the development in lipomas based on a breakpoint translocation 
61. Another study could show, that HMGA2 plays a role in the adipocytic cell growth and 
development 62 and Hmga2 knockout mice developed a pygmy phenotype with a strong 
reduction of body weight by affecting the AT 63. 
Interestingly, variation in body FD between ethnic groups have been observed among pre-
pubertal children. Asian girls and boys were described to have less extremity and/or gynoid fat 
compared with Caucasian and African-American children of the same sex and age 64 (Figure 
1). Another example for ethnic differences in AT distribution is the South African group 
Khoikhoi, whose women present an increased accumulation of AT in the buttocks 65 .  
 
The genetic heritability of FD patterns cannot be explained only by mutations and single 
nucleotide polymorphisms (SNPs). Additional factors, like non-coding RNAs and epigenetic 
modifications like DNA and histone methylation may play an important role (Figure 1). The 
term “epigenetics” defines heritable changes in gene expression without any changes of the 
DNA sequence itself 66. Epigenetic marks are tissue specific and can mediate biological and 
biochemical processes such as imprinting, which determine expression of alleles according to 
the maternal or paternal origin and balance the expression 67,68. Defects in imprinting result in 
altered gene expression. For instance, a paternal deletion at 15q11-q13 due to imprinting results 
in the Prader-Willi syndrome, which is among others characterized by severe early onset obesity 
caused by hyperphagia 69.  
The DNA methylation is a post-replication modification and mostly found at cytosines followed 
by a guanine, the so called CpG sites. Especially methylation/demethylation of CpG sites in the 
promotor region can affect the gene expression 67. There is growing evidence that obesity and 
body FD is also controlled by DNA methylation. For instance, Keller et al. have recently shown 
depot-specific global DNA methylation levels in ScAT and VAT accompanied by positive 
correlations between the DNA methylation in ScAT with WC and WHR 70. 
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1.3. Genome wide associations studies (GWAS) 
Genetic loci associated with quantitative traits are referred to as quantitative trait loci (QTL) 71. 
QTL mapping is a phenotype-driven method that reveals statistical associations between 
genotypes and phenotypic values for a quantitative trait of interest. It helps to understand the 
genetic architecture of trait variation and uncovers new possible candidate genes involved in 
the regulation of traits of interest 72. With the development of high-throughput genotyping 
technologies it became possible to run GWAS, an unbiased approach to identify novel 
statistically significant loci associated with obesity or body FD 73. One of the first studies related 
to body FD showed an association of rs12970134 with WC in subjects of Indian-Asian or 
European ancestry 74. This SNP is located near melanocortin 4 receptor (MC4R), whose 
mutations are also known to be the major determinants of monogenic obesity 74.  
The first meta-analysis of GWAS for WC and WHR was reported from Lindgren et al.75 who 
could show that genetic factors play a role in the regulation of WC and WHR. In 2010, Heid et 
al. published a meta-analysis including 32 GWAS with up to 77,167 participants for WHR 
adjusted for BMI, which revealed 14 genetic loci (vascular endothelial growth factor A 
[VEGFA], ADAM metallopeptidase with thrombospondin type 1 motif 9 [ADAMTS9], R-
spondin 3 [RSPO3], T-box 15- tryptophanyl-tRNA synthetase [TBX15-WARS], nuclear factor, 
erythroid 2 like 3 [NFE2L3], lymphocyte antigen 86 [LY86], growth factor receptor bound 
protein 14 - cordon-bleu WH2 repeat protein like 1 [GRB14-COBLL1], inositol 1,4,5-
trisphosphate receptor type 2- sarcospan [ITPR2-SSPN], dynamin 3- phosphatidylinositol 
glycan anchor biosynthesis class C [DNM3-PIGC], homeobox C13 [HOXC13], zinc and ring 
finger 3- kringle containing transmembrane protein 1 [ ZNRF3-KREMEN1], nischarin- stabilin 
1 [ NISCH-STAB1], cytoplasmic polyadenylation element binding protein 4 [ CPEB4]) 
including the known locus at lysophospholipase like 1 (LYPLAL1) associated with the 
measurements of FD 38. Interestingly, seven of these loci revealed stronger effects in women 
than in men. In 2015, a new meta-analysis of GWAS of WHRadjBMI showed additional loci 
76. In this study, 142,762 individuals of European ancestry from 57 previously described 38 or 
new GWAS, and further 67,326 European individuals from Metabochip studies were included. 
As a result the authors identified 49 loci for WHRadjBMI with 33 new loci and nine additional 
loci in sex-specific analysis, eight were only significant in women and not in men 76. The 16 
previously described variants were confirmed as well. Both reported meta-analyses showed 
significantly larger heritability and effect estimates in women than in men 38,76. Furthermore, 
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Shungin et al. aimed to find a link between central obesity and the higher risk for metabolic 
disorders and therefore investigated the leading WHRadjBMI SNPs in association for 22 
additional traits from the GWAS data 76. 17 out of the 49 variants showed a significant 
association with at least one of the metabolic traits (high-density lipoprotein cholesterol [HDL] 
- 7 SNPs; TG - 5 SNPs; low-density lipoprotein cholesterol [LDL]-2 SNPs; fasting insulin - 3 
SNPs). Also, nominal associations (p<0.05) were shown with traits like fasting and 2 -h 
glucose, diastolic and systolic blood pressure, BMI and coronary artery disease 76. Free 
available databases were used to assess the functionality of the WHRadjBMI variants and 
revealed that at eleven of the new loci the lead SNPs were in linkage disequilibrium (LD) with 
cis-expression quantitative trait loci (eQTL) in ScAT and/or omental AT, liver or blood cell 
types 76. Further, the variants were investigated for their location in open chromatin regions in 
different tissues like AT, liver or blood. At least one variant in seven of the elven loci resided 
in a putative regulatory element, suggesting its regulatory role in gene expression. Three 
approaches (GRAIL77, MAGENTA 78, DEPICT 79) were used to highlight the related target 
genes and pathways for the identified loci suggested following members: signaling pathways 
involving vascular endothelial growth factor (VEGF), phosphatase and tensin (PTEN) 
homologue, the insulin receptor (IR), and peroxisome proliferator-activated receptors (PPARs) 
76. Further, gene sets, which may have a role in body fat regulation like insulin sensitivity and 
glucose level regulation were highlighted.  
It is of note that GWAS of body FD based on more precise measurements such as CT have been 
recently performed 80. In one of the first studies of this kind, Fox et al. confirmed previously 
reported loci (LYPLAL1 - for VAT/ScAT ratio, FTO - ScAT), but also identified a novel variant 
for VAT near threonine synthase like 2 (THNSL2) specifically affecting FD in women only 
(rs1659258) 80.  
Not only cohorts of European ancestry were investigated but also association studies in various 
ethnic groups were performed in the past. In a study with a cohort of African ancestry, two new 
loci, associated with WCadjBMI (LIM homeobox 2 [LHX2]) and WHRadjBMI (Ras responsive 
element binding protein 1 [RREB1]) were identified and six of the 14 “European” loci were 
confirmed (TBX15-WARS2, GRB14, ADAMTS9, LY86, RSPO3, ITPR2-SSPN) 81. Hotta et al. 
investigated the reported SNPs in a cohort of Japanese ancestry and demonstrated that 
LYPLAL1 and NISCH might influence FD in this population 82.  
Additionally, GWAS for other AT related traits like ectopic fat traits (ScAT, VAT,VAT/ScAT 
ratio etc.) 83, pericardial fat 84 or body fat percentage 85 were performed to demonstrate new loci 
(e.g. Ataxin 1 [ATXN1], Tribbles pseudokinase 2 [TRIB2]) and to confirm some of the reported 
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loci (e.g. CPEB4, GRB14-COBLL1). In the last years also epigenome wide associations studies 
(EWAS) for BMI have been conducted, implicating the close relationship between DNA 
methylation and obesity 86. The hypoxia inducible factor 3A (HIF3A) was the most prominent 
gene, whose DNA methylation at corresponding CpG sites showed strong association with BMI 
86. 
 
1.4. Candidate genes 
Majority of obesity cases are attributed to the polygenic nature of this disease and also the body 
FD is affected by numerous genetic variants in various genes. Identification and understanding 
of the causal variants/genes and their mutual interaction is one of the major challenges in 
functional genetics. Despite the fact that SNPs usually render small effects, they still can play 
an important role in the complex etiology of diseases and can help to understand the underlying 
molecular pathomechanisms. Genetic variants and associated loci/genes from GWAS/EWAS 
and meta-analyses of GWAS provide a powerful resource for further research on individual 
candidate genes aimed to clarify the underlying molecular mechanisms in the regulation of body 
FD as well as the causal relationship between abdominal fat accumulation and the higher risk 
for metabolic diseases 76 (Figure 1).  
 
 1.4.1. Hypoxia inducible factor 3 A (HIF3A) 
Obesity is related to chronic inflammation in AT, which contributes to insulin resistance and 
impaired glucose and lipid metabolism 87. The inflammation affects different pathways and 
metabolic conditions like hypoxia, which can ultimately lead to AT dysfunction. The improved 
knowledge on combined effects of genetic factors and epigenetic alterations can help to better 
understand the pathophysiology of obesity and FD. Dick et al. performed a study that showed 
genome wide significant associations between DNA methylation in blood and BMI 86. DNA-
methylation at three of five CpG sites most strongly associated with BMI were located in intron 
1 in HIF3A. HIF3A is a component of the hypoxia inducible transcription factor (HIF). HIFs 
are heterodimeric constructs consisting of hypoxia-regulated α and oxygen-insensitive β 
subunits and mediating many cellular responses during hypoxia 88. Whereas family members 
HIF1α and HIF2α have been extensively investigated in the past, much less is known about 
HIF3α. In humans, HIF3A, the HIF3α encoding gene, is located on chromosome 19q13.2 and 
is represented by six protein coding transcripts (Ensemble database 13.02.2018). Maynard et 
al. 89 detected HIF3A-transcripts in the heart, placenta, lung and skeletal muscle by using 
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Northern blot analysis, and Pasanen et al. showed HIF3A expression additionally in brain, liver, 
kidney and pancreas 90. The biology of HIF3α is very complex due to the different HIF3A 
variants, which are expressed in several tissues, at several time points and are differentially 
regulated by hypoxia and other factors 91. The HIF3A mRNA and protein levels increase during 
hypoxia in a tissue-specific manner mediated by HIF1A and/or HIF2A 92,93. On the other hand 
it was demonstrated that one HIF3A variant serves as a negative regulator of HIF1/2α 94. There 
are also oxygen-independent regulation pathways as has been shown by insulin or 2-deoxy-D-
glucose treatments resulting in higher HIF3A mRNA levels 95. Furthermore, oleic and linoleic 
acid can bind to the Per-Arnt-Sim (PAS)-B domain of HIF3A 96 and drive its regulation.  
HIF3A is a potential candidate gene based not only on the results from the above mentioned 
EWAS 97 but also on the corresponding biological pathways. In my study, I conducted mRNA 
expression and DNA methylation analyses of the reported CpG sites in human VAT and ScAT. 
Furthermore, the genotypes of HIF3A polymorphisms rs8102595 and rs3826795 were analyzed 
for associations with anthropometric and metabolic parameters.  
1.4.2. Replication initiator 1 (REPIN1) 
In 1998 Kovacs et al. reported a QTL for serum fasting insulin, TG and body weight in rats on 
chromosome 4 98. One of the most plausible candidate genes within this locus is the zinc finger 
protein replication initiator 1 (REPIN1). The human REPIN1 is located on chromosome 7 and 
consists of four exons including one coding. Eleven protein coding transcripts are listed in the 
Ensembl database, four of them are annotated in the NCBI reference sequence (RefSeq). The 
transcription results in a 64 kDa Protein composed of 567 or 624 amino acids (NM_013400, 
NM_001099696, NM_014374, NM_001099695, Ensemble database 13.02.2018). REPIN1 is 
ubiquitously expressed with highest expression reported in liver and AT 99. Repin1 has been 
extensively investigated in liver and AT-specific knock-out mouse models 100,101. Briefly, the 
liver- as well as the AT-specific model show a metabolic healthier phenotype compared with 
the wildtype mice. The repin1 knockout mice are more insulin sensitive, have reduced AT mass 
and an improved lipid metabolism represented by lower LDL and total cholesterol levels 100,101 
. In another study it was shown that Repin1 knockdown in 3T3-L1 cells results in smaller 
adipocytes, reduced basal but revised insulin stimulated glucose uptake, and changes in mRNA 
expression of genes which are involved in adipogenesis, lipid uptake and lipid droplet formation 
102. All these data were generated in mice, whereas human data are lacking so far. Therefore, in 
the present study I investigated the role of genetic variation within human REPIN1 on glucose 
and lipid metabolism.  
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1.4.3. Iriquois homeobox 3/5 (IRX3/5) 
In 2007, the most significant hit in the GWAS for obesity, especially for BMI, was reported 
within the fat mass and obesity associated gene (FTO) locus 103. Independent studies confirmed 
different common variants (i.e. rs9939609 104, rs9930506 103) in intron 1 of the FTO and their 
associations with BMI in the general population 104–106. On the other hand Klöting et al. 
demonstrated an inverse relationship of FTO mRNA expression and BMI in human AT 107. In 
2014, Smemo et al. showed that FTO has a long range connection to iroquios homebox 3 (IRX3) 
108. The obesity related region in intron 1 of FTO interacts directly with the promotor of IRX3 
108. In line with this, Irx3 deficient mice exhibited a 25-30 % reduced body weight through the 
loss of fat mass 108. Consistently, Claussnitzer et al. demonstrated a link between FTO variants 
and IRX3 and IRX5 109. With the help of different bioinformatic tools (i.e. Roadmap 
Epigenomics 110, ENCODE 111) they found IRX3 and IRX5 as the genes most likely affected by 
the obesity-associated FTO-variants. They confirmed this in in vitro studies and showed that 
both genes were affected by the risk alleles of the FTO-variants in human adipocytes 109. IRX3 
is located on chromosome 16 and has one protein-coding transcript (NM_024336). This 
transcript contains four coding exons that are translated into a 501 amino acid protein. IRX5 
displays four protein coding transcripts according to the Ensembl database but only one 
possesses an NCBI RefSeq entry (NM_005853). This transcript with three coding exons results 
in a protein with 482 amino acids.  
In the present study I analyzed the mRNA expression levels of IRX3 and IRX5 in VAT and 
ScAT and tested for associations with a representative FTO variant and metabolic traits.  
1.4.4. Krüppel like factor 13 (KLF13) 
Shungin et al. reported in their GWAS 49 loci, which were associated with WHRadjBMI. 16 
were reported before, 33 loci were new and one of these was the Krüppel like factor 13 (KLF13) 
loci 76. KLF13 is located on chromosome 15 in humans. Three protein coding transcripts are 
described in the Ensembl database, one of them is annotated in the NCBI reference sequence 
(RefSeq). The transcript is composed by 288 amino acids (NM_015995, Ensemble database 
15.10.2018) in two coding exons. KLF13 belongs to the KLF family, which include 17 members 
(KLF1 - 17) 112. The KLF´s have three highly conserved Cy2/His2 zinc fingers and they bind to 
GC- and CACCC- boxes of DNA 113,112. The fingers are connected by the characteristic 
Krüppel-link, which is a seven-amino acid spacer TGEKP(Y/F)X 114. Most of the KLF´s are 
widely expressed but the mechanisms are not totally defined, although it is known that multiple 
members of the KLF family regulated the same processes but with opposing effects 115. KLF´s 
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can also regulate other family members; for example the expression of KLF3 is regulated by 
KLF1 in erythroid cells 116.  
In this study I analyzed the mRNA expression levels in VAT and ScAT of KLF13 and tested 
the reported SNP rs8042543 for association with metabolic traits. Moreover, I investigated the 
role of KLF13 in AT biology by employing its knockdown in epididymal and inguinal murine 
cells. 
1.5. Aim of the thesis 
In the last decades obesity and related diseases grew to a global health problem. One of the 
main predictors of obesity associated comorbidities is the body FD. Similar to obesity, there is 
good evidence that the body FD is controlled by genetic factors. Recent advances in high 
throughput genotyping and sequencing technologies allowed identification of candidate genes, 
which are involved in the polygenic regulation of FD. GWAS and EWAS uncovered multiple 
genetic variants, associated with measures of body fat composition like WHR and BMI, which 
are now targeted in detailed functional analyses.  
This thesis aims to clarify the role of HIF3A, REPIN1, IRX3, IRX5 and KLF13 as novel 
candidate genes in the pathogenesis of the human body FD (Figure 1). 
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4.1. Abstract 
Background 
The strongest signal for BMI in genome wide association studies maps in introns 1 and 2 of the 
FTO, alpha-ketoglutarate dependent dioxygenase gene (FTO, also: fat mass and obesity 
associated). Recent studies show that the variants do not exert their regulatory effect on the 
gene itself, but rather on the neighbouring genes IRX3 and IRX5. Therefore, we investigated the 
fat depot specific mRNA expression of IRX3 and IRX5 in relation to obesity and associated 
metabolic traits. 
Results 
IRX5 showed significantly higher expression in subcutaneous adipose tissue (ScAT) compared 
to visceral adipose tissue (VAT), whereas IRX3 demonstrated no differences between both 
depots. Furthermore, the ScAT mRNA expression of IRX3 was associated with obesity 
measures such as weight and BMI. No association was observed between the obesity-associated 
SNP rs8050136 and the expression levels of both genes. 
Conclusion 
Our analysis suggests a moderate relationship between the AT specific expression of IRX3 and 
IRX5 and obesity. 
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4.2. Introduction 
In 2007 the strongest signal in GWAS for BMI pointed out intron 1 of the fat mass and obesity 
associated gene (FTO) gene 2,3. Subsequently, numerous studies demonstrated that FTO 
polymorphisms were not only associated with BMI 4 but also with obesity related parameters 
and complications like the metabolic syndrome 5, hypertension 6 and atherosclerosis 7. Despite 
the strong and robustly replicated associations, the direct molecular mechanisms behind the 
FTO associations remained poorly understood. However, recent studies suggested that the 
reported FTO SNPs exert regulatory effects not only on FTO itself, but also on nearby genes 8. 
Initially, Smemo et al. showed a long range interaction between FTO and the iroquios homebox 
3 (IRX3) 9. The obesity-associated FTO SNPs in introns 1 and 2 interact directly with the 
promoters of IRX3 as well as FTO in humans. Irx3-deficient mice showed a 25–30 % reduction 
of body weight, primarily through the loss of fat mass. At the same time, the basal metabolic 
rate was increased through browning of the white AT 9. In line with findings by Smemo et al., 
Claussnitzer et al. 10 demonstrated a potential mechanistic pathway for the genetic variants in 
FTO, which seems to regulate the IRX3 and IRX5 expression in AT 10. 
To gain more insights into the role of IRX3 and IRX5 in obesity, we investigated the fat depot 
specific mRNA expression of IRX3 and IRX5 in relation to obesity and associated metabolic 
traits. 
4.3. Material and Methods 
4.3.1. Subjects 
Paired samples of ScAT and VAT were obtained from 551 participants who underwent open 
abdominal surgery. All AT samples were frozen immediately in liquid nitrogen and stored at -
80°C. Phenotypic characterization of the study participants including anthropometric 
measurements (weight, height, waist, hip circumference, WHR), bioimpedance analyses or 
dual-energy X-ray absorptiometry (body fat), and metabolic parameters (fasting plasma 
glucose, fasting plasma insulin, 75-g oral glucose tolerance test (OGTT), HbA1c, lipoprotein-, 
triglyceride-, free fatty acid- and adipokine serum concentrations) was performed as previously 
described 11,12. Measurement of abdominal VAT and ScAT areas was performed using 
computed tomography (CT) or MRI scans. For our analysis, data from 176 men and 375 women 
were available (mean age 50±13 years; mean BMI 44.1±13.1 kg/m²). 303 subjects had normal 
glucose tolerance (mean age 49±13 years; mean BMI 39.9±13.4 kg/m²), whereas 224 subjects 
manifested with T2D (mean age 52±11 years; mean BMI 49.4±10.4 kg/m²) (Table 1). The study 
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was approved by the ethics committee of the University of Leipzig and all participants gave 
written informed consent before taking part in the study. 
 
Table 1. Anthropometric and metabolic characteristics of the study participants 
 Total NGT T2D 
N 551 303 224 
Men/Women 176/375 93/210 77/147 
Age (years) 50±13 49±15 52±11 
BMI (kg/m2) 44.1±13.1 39.9±13.4 49.4±10.4 
Weight (kg) 127.7±41.4 115.2±42.9 142.9±33.2 
Waist (cm) 126.9±29.2 114.0±29.6 143.3±21.4 
WHR 0.94±0.10 0.90±0.08 1.03±0.08 
Body fat (%) 42.6±11.5 38.1±13.9 45.89±8.15 
Visceral fat area (cm²) 243.5±182.9 177.7±152.2 410.4±150.5 
Subcutaneous fat area (cm²) 1094.21±807.7 945.0±835.1 1467.5±617.9 
Fasting plasma glucose (mmol/l) 6.74±2.83 5.53±1.17 8.46±3.52 
Fasting plasma insulin (pmol/l) 118.12±131.2 67.70±68.8 168.9±156.9 
120 min plasma glucose (mmol/l) 6.72±2.14 6.26±0.99 12.72±6.93 
HbA1c (%) 6.17±1.2 5.51±0.5 7.06±1.4 
GIR (µmol/kg/min) 76.95±32.35 90.35±21.05 36.15±27.26 
Total cholesterol (mmol/l) 5.07±1.09 5.05±1.08 5.05±1.05 
LDL-cholesterol (mmol/l) 3.09±0.88 3.12±0.88 3.00±0.85 
HDL-cholesterol (mmol/l) 1.25±0.37 1.37±0.43 1.15±0.31 
Triglycerides (mmol/l) 1.96±1.24 1.54±1.12 2.30±1.21 
Free fatty acids (mmol/l) 0.59±0.40 0.39±0.34 0.89±0.31 
Leptin (ng/ml) 38.97±25.44 34.53±23.77 43.17±27.13 
Adiponectin (µg/ml) 6.67±4.64 8.55±4.98 4.43±3.11 
IL6 (pg/ml) 6.31±5.4 5.33±4.70 7.89±6.20 
Table continued on the next page 
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 Total NGT T2D 
Max. adipocyte size vis (µm) 200.21±23.4 198.37±27.13 202.22±18.28 
Max. adipocyte size sc (µm) 203.3±21.9 200.75±25.11 206.42±17.26 
Mean adipocyte size vis (µm) 126.56±17.7 122.15±19.68 131.74±13.37 
Mean adipocyte size sc (µm) 130.5±17.6 124.77±18.71 137.56±13.5 
BMI- body mass index, WHR- waist-to-hip ratio, IL-6- interleukin 6, HbA1c- Glycohemoglobin, GIR- glucose 
infusion rate during the steady state of an euglycemic hyperinsulinemic clamp, HDL- high density lipoprotein 
cholesterol, LDL- low density lipoprotein cholesterol , Vis mean- mean adipocyte size in visceral adipose tissue, 
Sc mean- mean adipocyte size in subcutaneous adipose tissue, Vis max- maximum adipocyte size in visceral 
adipose tissue, Sc max- maximum adipocyte size in subcutaneous adipose tissue 
 
4.3.2. Measurement of human IRX3 and IRX5 mRNA expression  
The mRNA expression of IRX3 and IRX5 was measured with specific primers (IRX3-
CTCTCCCTGCTGGGCTCT CAAGGCACTACAGCGATCTG; IRX5-
GACCTGGAGAAGAACGACGA GCCTTCTGCTCAGCTCCTC) by qRT-PCR (Applied 
Biosystems, Darmstadt, Germany). Total RNA was isolated from AT samples using the 
Qiacube System (Qiagen, Hilden, Germany), and 2 µg RNA was reverse transcribed with 
standard reagents (Life Technologies). The expression levels of IRX3 and IRX5 were calculated 
relative to the mRNA expression of hypoxanthine guanine phosphoribosyltransferase 1 
(HPRT1), determined by the assay (Applied Biosystems, Darmstadt, Germany, 
Hs01003267_M1). Expression of IRX3, IRX5 and HPRT1 mRNA were quantified by using the 
second standard curve based method of the TaqMan Software (Applied Biosystems).  
 
4.3.3. Genotyping of FTO SNP rs8050136 
Genomic DNA was extracted from blood samples using the QuickGene DNA whole blood kit 
(Kurabo, Japan). Genotyping of the SNPs rs8050136 was performed using the TaqMan SNP 
Genotyping assay (Applied Biosystems;  C_2031259_10). To assess genotyping 
reproducibility, a random ~5 % selection of the sample were re-genotyped for all SNPs; all 
genotypes matched initial designated genotypes. Rs8050136 belongs to one L.D. group, which 
includes the previously reported BMI-associated SNP rs9939609 2. 
4.3.4. Statistical analysis 
Statistical analyses were done with SPSS (SPSS, version 24, Inc., Chicago, IL, USA). All non-
normally distributed parameters were logarithmically transformed to approximate a normal 
distribution. To analyze differences in mRNA expression levels between IRX3 and IRX5 
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expression in VAT and ScAT, paired two-tailed t-tests were applied. To test for group 
differences, two tailed t-tests was used. Pearson’s correlation coefficients were used to assess 
bivariate correlation with phenotypes related to obesity, fat distribution and glucose and insulin 
metabolism. Linear regression models were used to control for confounders such as age, gender 
and BMI. Linear regression analysis adjusted for respective covariates was applied to analyze 
rs8050136 for genetic association with mRNA expression and metabolic traits. 
4.4. Results and Discussion 
4.4.1. Correlation of IRX3 and IRX5 mRNA expression with metabolic parameters 
The mRNA expression of IRX3 in ScAT was positively correlated with weight and BMI, and 
remained significant even after adjustment for sex and age. Although waist correlated with 
subcutaneous IRX3 expression, the correlation did not withstand adjustments for age and sex. 
Similarly, the IRX3 mRNA in VAT showed correlations with weight, BMI and waist only if the 
relevant covariates are not taken into account (Table 2).  
Table 2. Correlation of IRX3 mRNA expression in adipose tissue with metabolic traits 
IRX3 Subcutaneous AT Visceral AT 
 
Trait R unadj. 
p-value 
adj. 
p-value 
R unadj. 
p-value 
adj. 
p-value 
Weight (kg) 0.168 2.49*10-3 0.021# 0.116 0.037 0.355# 
BMI (kg/m²) 0.180 1.22*10-3 0.015# 0.130 0.019 0.248# 
Waist (cm) 0.181 0.037 0.554 0.167 0.049 0.804# 
WHR -0.091 0.349 0.876# -0.095 0.310 0.635# 
% Body fat 0.077 0.546 0.624# 0.139 0.271 0.618# 
Vis fat (cm²) 0.075 0.449 0.750 0.128 0.181 0.741 
Sc fat (cm²) 0.155 0.116 0.929 0.117 0.224 0.686 
FPG (mmol/l) -0.103 0.070 0.061 -0.030 0.604 0.746 
FPI (mmol/l) 0.004 0.974 0.421 0.130 0.227 0.793 
oGTT2h (mmol/l) -0.103 0.360 0.163 -0.072 0.511 0.374 
GIR (µmol/kg/min) 0.295 0.017 0.128 0.103 0.392 0.910 
HbA1c (%) -0.079 0.305 0.182 -0.050 0.505 0.199 
Chol (mmol/l) -0.012 0.863 0.927 0.015 0.838 0.701 
HDL (mmol/l) 0.007 0.939 0.109 0.001 0.992 0.096 
LDL (mmol/l) 0.110 0.240 0.379 0.041 0.654 0.950 
TG (mmol/l) -0.008 0.906 0.340 0.034 0.635 0.907 
FFA (mmol/l) -0.030 0.788 0.103 0.108 0.324 0.806 
Leptin (ng/ml) 0.249 0.014 0.392 0.196 0.052 0.526 
Adiponectin (µg/ml) -0.092 0.369 0.750 -0.156 0.121 0.606 
IL6 (pg/ml) 0.280 0.016 0.061 0.119 0.295 0.746 
Table continued on the next page 
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IRX3 Subcutaneous AT Visceral AT 
 
Trait R unadj. 
p-value 
adj. 
p-value 
R unadj. 
p-value 
adj. 
p-value 
Vis mean (cm²) 0.060 0.614 0.447 0.009 0.941 0.960# 
Sc mean (cm²) 0.052 0.660 0.561 0.072 0.539 0.510# 
Vis max (cm²) 0.037 0.757 0.557 -0.162 0.162 0.172# 
Sc max (cm²) -0.091 0.439 0.581# -0.074 0.527 0.606# 
The data are given as mean ± standard deviation, p-values are adjusted for sex, age and BMI, 
# p-value adjusted for sex and age, bold p-values indicate statistical significance.  
R- correlation coefficient, AT- adipose tissue, BMI- body mass index, WHR- waist-to-hip ratio, TG- 
triglycerides, IL-6- interleukin 6, HbA1c- glycohemoglobin, oGTT- oral glucose tolerance test, FPG- fasting 
plasma glucose, FPI- fasting plasma insulin, GIR- glucose infusion rate during the steady state of an euglycemic 
hyperinsulinemic clamp, HDL- high density lipoprotein cholesterol, LDL- low density lipoprotein cholesterol , 
FFA- free fatty acids, Sc- subcutaneous, Vis- visceral, Vis mean- mean adipocyte size in visceral adipose tissue, 
Sc mean- mean adipocyte size in subcutaneous adipose tissue, Vis max- maximum adipocyte size in visceral 
adipose tissue, Sc max- maximum adipocyte size in subcutaneous adipose tissue. 
 
For the subcutaneous IRX5 mRNA levels no significant correlations with metabolic parameters 
were found. The mRNA expression of IRX5 in VAT showed significant correlations with BMI 
and waist but only in the unadjusted model (Table 3).  
 
Table 3. Correlation of IRX5 mRNA expression in adipose tissue with metabolic traits 
IRX5 Subcutaneous AT Visceral AT 
 
Trait R unadj. 
p-value 
adj. 
p-value 
R unadj. 
p-value 
adj. 
p-value 
Weight (kg) 0.006 0.923 0.677# 0.112 0.053 0.107# 
BMI (kg/m²) 0.021 0.725 0.932# 0.130 0.025 0.069# 
Waist (cm) -0.094 0.322 0.167# 0.227 0.014 0.128# 
WHR -0.043 0.692 0.782# 0.014 0.892 0.757# 
% body fat 0.033 0.810 0.286# 0.283 0.033 0.644# 
Vis fat (cm²) -0.180 0.102 0.068# 0.169 0.111 0.294# 
Sc fat (cm²) -0.082 0.458 0.309# 0.111 0.299 0.816# 
FPG (mmol/l) -0.089 0.136 0.244 0.028 0.640 0.664 
FPI (mmol/l) -0.129 0.282 0.162 0.260 0.025 0.152 
oGTT2h (mmol/l) 0.004 0.973 0.973 0.051 0.670 0.781 
GIR (µmol/kg/min) 0.284 0.044 0.366 -0.039 0.775 0.514 
HbA1c (%) 0.009 0.911 0.535 -0.019 0.816 0.232 
Chol (mmol/l) -0.20 0.790 0.919 0.092 0.219 0.158 
HDL (mmol/l) 0.065 0.509 0.147 -0.093 0.332 0.654 
LDL (mmol/l) -0.032 0.744 0.700 0.136 0.157 0.303 
TG (mmol/l) -0.015 0.836 0.695 0.017 0.817 0.667 
FFA (mmol/l) 0.032 0.800 0.659 0.108 0.372 0.661 
Table continued on the next page 
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IRX5 Subcutaneous AT Visceral AT 
 
Trait R unadj. 
p-value 
adj. 
p-value 
R unadj. 
p-value 
adj. 
p-value 
Leptin (ng/ml) 0.013 0.905 0.112 0.209 0.055 0.309 
Adiponectin (µg/ml) 0.064 0.565 0.756 -0.153 0.161 0.552 
IL6 (pg/ml) 0.220 0.091 0.033 0.062 0.624 0.920 
Vis mean (cm²) -0.066 0.587 0.690 0.052 0.671 0.648 
Sc mean (cm²) 0.033 0.782 0.812 0.026 0.831 0.860 
Vis max (cm²) -0.073 0.551 0.623 -0.132 0.276 0.305 
Sc max (cm²) 0.089 0.459 0.341 -0.122 0.313 0.328 
The data are given as mean ± standard deviation, p-values are adjusted for sex, age and BMI,# 
p-value adjusted for sex and age, bold p-values indicate statistical significance. 
R- correlation coefficient , AT- adipose tissue, BMI- body mass index, WHR- waist-to-hip ratio, TG- 
triglycerides, IL-6- interleukin 6, HbA1c- glycohemoglobin, oGTT 2h- oral glucose tolerance test measurement 
after 2 hours, FPG- fasting plasma glucose, FPI- fasting plasma insulin, GIR- glucose infusion rate during the 
steady state of an euglycemic hyperinsulinemic clamp, HDL- high density lipoprotein cholesterol, LDL- low 
density lipoprotein cholesterol , FFA- free fatty acids, Sc- subcutaneous, Vis- visceral, Vis mean- mean 
adipocyte size in visceral adipose tissue, Sc mean- mean adipocyte size in subcutaneous adipose tissue, Vis max- 
maximum adipocyte size in visceral adipose tissue, Sc max- maximum adipocyte size in subcutaneous adipose 
tissue. 
4.4.2. Differences of IRX3 and IRX5 mRNA expression in subcutaneous and visceral 
adipose tissue 
We did not find a difference in the mRNA expression levels of IRX3 between ScAT and VAT 
in our cohort (Figure 1A). The mRNA expression levels were near the same in both ATs in the 
subgroups of subjects with normal glucose tolerance (NGT) and also in the subgroup of subjects 
with T2D. There were also no differences observed in expression levels in lean or obese subjects 
(Figure 1B). 
Figure 1. mRNA expression levels of IRX3 in subcutaneous (ScAT) and visceral (VAT) adipose tissue. The 
analysis were done in the total cohort, in subjects with normal glucose tolerance (NGT) and subject with type 2 
diabetes (T2D) (A) and in lean (BMI<25 kg/m²) and obese (BMI>30 kg/m²) subjects (B). 
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The mRNA expression levels for IRX5 differ between both tissues. We observed significantly 
higher levels in the ScAT compared to the VAT and these findings were also observed in the 
subgroups of subjects with NGT and T2D (Figure 2A). Consistently, we found differential 
mRNA expression in ScAT vs. VAT in both, lean and obese subjects (Figure 2B). 
Figure 2. mRNA expression levels of IRX5 in subcutaneous (ScAT) and visceral (VAT) adipose tissue. The 
analysis were done in the total cohort, in subjects with normal glucose tolerance (NGT) and subject with type 2 
diabetes (T2D) (A) and in lean (BMI<25 kg/m²) and obese (BMI>30 kg/m²) subjects (B).***p<0.001 
 
4.4.3. Association of rs8050136 with metabolic traits 
Rs8050136 showed only a moderate association with BMI (p=0.057). Furthermore, it was 
associated with obesity measures such as weight, waist and hip (Table 3). The SNP was not 
associated with the mRNA expression levels of IRX3 and IRX5, although a tendency was 
observed for the IRX3 mRNA expression in VAT with a p value of 0.077 (Table 4). 
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Table 4. Association of rs8050136 with metabolic traits 
The data are given as mean ± standard deviation, p-values are adjusted for sex, age and BMI,# 
p-value adjusted for sex and age, bold p-values indicate statistical significance. 
AT- adipose tissue, BMI- Body mass index, WHR- waist-to-hip ratio, TG- triglycerides, IL-6- interleukin 6, 
HbA1c- glycohemoglobin, oGTT 2h- oral glucose tolerance test measurement after 2 hours, FPG- fasting plasma 
glucose, FPI- fasting plasma insulin, GIR- glucose infusion rate during the steady state of an euglycemic 
hyperinsulinemic clamp, HDL- high density lipoprotein cholesterol, LDL- low density lipoprotein cholesterol , 
FFA- free fatty acids, Sc- subcutaneous, Vis- visceral, Vis mean- mean adipocyte size in visceral adipose tissue, 
Sc mean- mean adipocyte size in subcutaneous adipose tissue, Vis max- maximum adipocyte size in visceral 
adipose tissue, Sc max- maximum adipocyte size in subcutaneous adipose tissue. 
. 
4.5. Summary 
In the present study we investigated the fat depot specific mRNA expression levels of IRX3 and 
IRX5 as plausible candidate genes for obesity and their link to related traits. We showed 
differential expression profiles for IRX5 in ScAT and VAT but not for IRX3. We confirmed an 
association between IRX3 expression levels in ScAT but found no association in VAT. We did 
not find a significant correlation between the mRNA expression of IRX3 and IRX5 with the 
obesity related SNP rs8050136. One explanation might be the restricted statistical power due 
 rs8050136 
Trait AA AC CC adj. p-value 
BMI (kg/m²) 44.5±12.0 40.0±14.0 39.0±13.1 0.057# 
% body fat 44.6±8.9 40.5±12.8 42.3±12.0 0.323 
Weight (kg) 127.9±37.9 116.3±43.9 112.6±41.4 0.034# 
Waist (cm) 126.4±25.1 115.5±28.6 112.5±29.9 1.23x10-3# 
Hip (cm) 140.0±27.0 129.0±30. 125.0±30.5 3.00x10-3# 
WHR 0.90±0.08 0.89±0.10 0.90±0.10 0.290 
FPG (mmol/l) 5.43±0.78 5.34±0.66 5.43±0.79 0.678 
FPI (mmol/l) 91.5±61.5 85.7±72.7 103.49±78.1 0.360 
GIR (µmol/kg/min) 84.4±17.9 92.0±21.6 90.3±26.9 0.179 
HbA1c (%) 5.53±0.46 5.43±0.44 5.43±0.38 0.452 
Chol (mmol/l) 4.77±0.95 4.84±1.05 4.71±1.05 0.447 
HDL (mmol/l) 1.28±0.34 1.32±0.44 1.33±0.47 0.464 
LDL (mmol/l) 3.07±0.81 3.14±1.00 2.91±1.02 0.273 
TG (mmol/l) 1.41±0.70 1.31±0.52 1.21±0.58 0.067 
FFA (mmol/l) 0.46±0.35 0.35±0.32 0.35±0.29 0.558 
Vis fat (cm²) 194.0±154.6 181.9±138.0 165.1±131.3 0.305# 
Sc fat (cm²) 1194.7±821.2 1011.0±830.5 905.1±806.7 0.102# 
Vis mean (cm²) 121.3±17.2 113.4±24.4 122.7±14.8 0.323 
Sc mean (cm²) 128.0±14.9 119.7±21.0 127.9±16.4 0.187 
Vis max (cm²)  218.0±77.8 209.8±76.8 204.0±33.7 0.649 
Sc max (cm²) 220.9±80.3 219.7±85.0 205.7±58.7 0.902 
logIRX3 sc 3.29±1.23 3.45±1.19 3.30±1.18 0.282 
logIRX3 vis 3.22±1.06 3.40±1.24 3.64±1.27 0.077 
logIRX5 sc 6.49±1.54 6.37±1.44 6.18±1.83 0.637 
logIRX5 vis 3.81±1.19 4.01±1.44 3.98±1.50 0.712 
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to the limited sample size caused by the fact that the overlap of the study group with expression 
data and the group of genotyped subjects was rather small (N=155). Further limitation of our 
study was that the mRNA expression was only measured in the whole extracted AT, since the 
adipocytes and the stroma vascular fraction (SVF) were not separated after the biopsies. 
Landgraf et al. showed an association between the FTO variant and IRX3 and IRX5 expression 
in adipocytes, but none were found in SVF or in the whole AT 13. Thus, lacking the separation 
of adipocytes might explain the missing associations in our study. Moreover, it would also be 
desirable to elucidate the role of IRX3 and IRX5 in the process of browning of AT as has been 
shown recently by Zou et al.14.  
In conclusion, our analysis suggests a moderate relationship between the AT specific expression 
of IRX3 and IRX5 and obesity. Further experiments focusing on specific cell types such as 
adipocytes as well as on processes like AT browning are warranted to better understand the role 
of these genes in the pathophysiology of human obesity. 
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Chapter 5  
KLF13 is a new candidate gene for the regulation of body fat distribution 
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5.1. Abstract 
Background 
In 2015 Shungin et al. reported 49 loci associated with waist-to hip-ration (WHR), suggesting 
that they might be involved in the regulation of body FD. One of these loci carries the rs8042543 
in KLF13. To better understand its role in the regulation of body fat composition, KLF13 
mRNA expression was measured in paired samples of human subcutaneous (ScAT) and visceral 
(VAT) adipose tissue from metabolically well-characterized subjects. Furthermore, the 
rs8042543 variant was genotyped in all study participants. Finally, Klf13 was silenced by 
siRNA in murine inguinal and epididymal preadipocytes to investigate the effect of Klf13 on 
adipogenesis. 
Results 
The mRNA expression of KLF13 was significantly higher in ScAT compared to VAT. The 
variant rs8042543 was significantly associated with WHR (adjusted for BMI), maximum 
adipocyte size in ScAT and VAT and with the subcutaneous KLF13 mRNA expression. The 
Klf13 siRNA mediated knockdown in murine inguinal and visceral preadipocytes showed 
moderate effects on the expression of Pparg and Cebpb. 
Conclusion 
The present data suggest a link between KLF13 and body FD, which might be driven by its 
regulatory role in adipocyte differentiation.  
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5.2. Introduction 
In 2015 Shungin et al. reported a GWAS showing 49 loci associated with WHR, which carry 
potential candidate genes influencing the body FD 1. Most of the candidate genes are implicated 
in adipose tissue (AT) pathways. For instance PPARG and CCAAT/enhancer binding protein 
alpha (C/EBPA) are essential for adipocyte differentiation 2 and bone morphogenic protein 2 
(BMP2) is crucial in mesenchymal stem cells fate towards adipogenesis or osteogenesis 3. 
Moreover, a number of genes encoding transcriptional regulators such as KLF13 seem to map 
to the WHR-associated loci. Adipogenesis contributes to specific fat depot mass and might 
thereby influence body FD. PPARG and C/EBPs are master regulators of these processes but 
many other factors play an important role in adipocyte differentiation, including members of 
the KLF family 4.  
The KLF family members share homology in their Cys2/His2 zinc finger-DNA binding 
domains allowing them to bind to GC-rich sequences and related CT or CACCC boxes in 
regulatory regions of target genes 5,6. 17 members have been identified in mammalian cells and 
classified as KLF1 - KLF17 7. It is known that multiple KLF’s  involved in the regulation of 
the same metabolic processes although they can also have opposing effects. One example is the 
adipogenesis regulation; KLF2 is required for the maintenance of preadipocytes and is 
downregulated during the differentiation 5. On the other hand KLF5 and KLF15 serve as 
positive regulators of adipogenesis 8,9. KLF13 was first identified as an activator of RANTES 
(CCL5) expression, a chemokine involved in the activated T-cell response 10. Jiang et al. 
showed that the Klf13 mRNA expression increased during differentiation in porcine adipocytes 
11. In porcine adipocytes KLF13 binds directly to PPARG and promotes the adipogenesis 
through this pathway.  
Based on the GWAS by Shungin et al., KLF13 is a candidate gene for the body FD 1. Moreover, 
there is a strong evidence that KLF family members including KLF13 are involved in 
adipogenesis 5,11. To better understand its role in the regulation of body fat composition, I 
measured KLF13 mRNA expression in paired samples of human ScAT and VAT from 
metabolically well-characterized subjects. Furthermore, I genotyped the rs8042543 variant in 
all study participants to assess its possible link to the mRNA expression pattern. Finally, I 
employed siRNA mediated knockdown of Klf13 in murine inguinal and epididymal 
preadipocytes to investigate its effect on adipogenesis. 
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5.3. Materials and Methods 
5.3.1. Subjects 
KLF13 mRNA expression was measured in paired ScAT and VAT samples obtained from 463 
German subjects. The samples were taken from individuals undergoing different types of 
abdominal surgeries. All patients gave their written informed consent and the study was 
approved by the ethical committee of the University of Leipzig. The mean age of the cohort 
was 48±13 years and the mean BMI was 46.0±11.9 kg/m². In the analysis 211 subjects (mean 
age 47±15 years, mean BMI 42.1±13.0) with normal glucose tolerance (NGT) and 212 subject 
(mean age 50±11 years, mean BMI 50.1±9.7) with type 2 diabetes (T2D) were included. 
Characterization of the study participants including anthropometric measurements, (weight, 
height, WHR), body fat analysis using bioimpedance analyses or dual-energy X-ray 
absorptiometry and metabolic parameters such as fasting plasma glucose and insulin, a 75 g 
oral glucose tolerance test (OGTT), HbA1c, lipoprotein-, triglyceride-, free fatty acid- and 
adipokine serum concentrations was performed as previously described 12,13. Measurement of 
abdominal VAT and ScAT areas was performed using CT or MRI scans. 
5.3.2. Measurement of KLF13 
The human KLF13 mRNA expression was measured by qRT-PCR using TaqMan Gene 
Expression Assay (Applied Biosystems, Darmstadt, Germany) and normalized to HPRT1. Total 
RNA was isolated from AT samples using the Qiacube System (Qiagen, Hilden, Germany), and 
2 μg RNA were reverse transcribed with standard reagents (Life Technologies). Expression of 
KLF13 and HPRT1 mRNA were quantified by using the second derivative maximum method 
of the TaqMan Software (Applied Biosystems). 
 
5.3.3. Genotyping of rs8042543 
Genomic DNA was extracted from blood using the QuickGene DNA whole blood kit (Kurabo, 
Japan). Genotyping of rs8042543 (C/T), which is located in the intron 2 of KLF13, was 
performed using the TaqMan SNP Genotyping assay (Applied Biosystems; C_2911174_10). A 
random ~5 % selection of the sample were re-genotyped for all SNPs to assess genotyping 
reproducibility; all genotypes matched initial designated genotypes.  
5.3.4. Cell culture 
For cell culture experiments SV40 T-antigen immortalized murine preadipocytes isolated from 
inguinal and epididymal white AT of C57BL/6 mice were used 14. The cells were kindly 
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provided by Prof. Dr. Johannes Klein and Dr. Nina Perwitz from the University of Lübeck. The 
murine inguinal and epididymal preadipocytes correspond to human subcutaneous and visceral 
preadipocytes and were therefore used for the further experiments. Both cell types were grown 
in growth medium (DMEM high; 20 % FBS) in humidified atmosphere of 5 % CO2 at 37 °C. 
The medium was normally changed every second day. At a confluence of 80-90 %, the cells 
were harvested and transfected with siRNA. When the cells became 100 % confluent the 
adipocyte differentiation was induced by changing medium to induction medium containing 0.5 
mM IBMX, 2 µg/ml dexamethasone, 0.125 mM indomethacin, 20 mM insulin and 1 nM T3 for 
48 h. Subsequently cells were additionally differentiated in differentiation medium (growth 
medium, 20 nM insulin and 1 nM T3) for six days.  
5.3.5. siRNA knockdown of Klf13 
The cells were transfected using the Neon Transfection system (Invitrogen). Cells were 
detached using trypsin and cell density was adjusted to 1x106 cells per 100 µL. 10 µl of 20 mM 
siRNA (GE Dharmacon, Freiburg, Germany) were added to cell suspension and transfection 
was carried out with two 20 ms pulses of 1300 V. Three different preparations were used: Klf13- 
siRNA (ON-TARGETplus siRNa-SMARTpool Mouse Klf13 [50794]), non- targeting Control 
siRNA (ON TARGETplus Non-targeting Control Pool) and Gapdh- siRNA (ON-TARGETplus 
Gapdh Control) as a positive control. Two transfections for every preparation were done. The 
treated cells were resuspended in growth medium and distributed on plates accordingly (Table 
1). After 72 h the cells were 100 % confluent and induced for differentiation. This 
differentiation timeline was done in triplicate. 
 
Table 1. Cell amount per well for different conditions 
condition Plate Cell amount 
RNA 12 well plate 80000 cells per well 
AdipoRed measurement 96 well plate 4500 cells per well 
Microscopy 24 well 40000 cells per well 
 
5.3.6. Lipid staining 
The intracellular lipid accumulation during the differentiation was measured by the 
AdipoRedTM assay (Lonza, Basel, CH). The cells were differentiated in 96 well plates and at 
the respective time point washed with PBS. Subsequently a mixture of 200 µl PBS 
(+Ca2+,+Mg2+, pH 7.4) and 5 µl AdipoRed was added to each well. The nuclei were stained 
with Hoechst (1µg/ml in MilliQ water) to normalize the AdipoRed signal. The fluorescence 
was measured in the FLUOstar OPTIMA (BMG LAPTECH) and the amount of 
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AdipoRed/Hoechst was analyzed subsequently. For microscopy the cells were also stained with 
AdipoRed™ at day eight. A mixture of 1ml PBS and 60 µl AdipoRed were added to each well 
of the 12 well plate. 
5.3.7. RNA isolation and reverse transcriptase PCR (RT-PCR) analysis 
The cells were treated with TRIzol® reagent (Invitrogen) according to the manufacturer´s 
instructions. To optimize the quality of RNA the RNase-free DNase Set from Qiagen and 
subsequently the RNeasy MinElute Cleanup Kit from Qiagen were used. 1 µg total RNA was 
reverse transcribed using SuperScript III First Strand Synthesis SuperMix for qRT-PCR 
(Thermo Fisher Scientific). cDNA was amplified and measured by qPCR using the TaqMan 
PCR system with selective TaqMan gene assays (KLF13[human]- Hs00429818_m1; 
HPRT1[human]-Hs01003267_m1; Klf13[mouse]-Mm00727486_s1; Hprt1[mouse]-
Mm01545399_m1; Pparg [mouse]-Mm01184322_m1; Gapdh [mouse]-Mm99999915_g1; 
Leptin [mouse]-Mm00434759_m1; Cebpb [mouse]-Mm00843434_s1). Specific mRNA 
expression was calculated relative to Hprt1 and was quantified by efficiency based calculation 
of relative gene expression as described by Pfaffl 15.  
5.4. Results and Discussion 
5.4.1. mRNA expression levels in AT correlate with metabolic traits and with rs8042543 
KLF13 showed significantly lower mRNA levels in ScAT compared to VAT in analysis with 
the total cohort and also in the subgroup of subjects with normal glucose tolerance (Figure 1A). 
In addition, the subjects with obesity had higher KLF13 mRNA expression levels in VAT than 
lean subjects (Figure 1B).  
Figure 1. The mRNA expression of KLF13 in ScAT and VAT. A The expression levels are shown in the total 
cohort, in subjects with normal glucose tolerance (NGT) and in subjects with type 2 diabetes (T2D). *** p< 
0.001. B The KLF13 mRNA expression in both adipose tissues in comparison of lean (BMI< 25 kg/m²) and 
obese (BMI> 30 kg/m²) subjects. * p< 0.05 
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The mRNA expression of KLF13 in both ATs correlated significantly with age. In VAT no 
further correlations were found. A significant correlation for the ScAT with weight (p=0.011) 
and BMI (p=0.013) (Table 2) was identified.  
Table 2. Correlation of KLF13 mRNA expression in ScAT and VAT with metabolic 
traits 
KLF13 Subcutaneous AT Visceral AT 
 
Trait R unadj. 
p-value 
adj. 
p-value 
R unadj. 
p-value 
adj. 
p-value 
Age (years) -0.143 0.037  -0.165 0.017  
Weight (kg) -0.082 0.235 0.011# 0.128 0.065 0.451 
BMI (kg/m²) -0.068 0.322 0.013# 0.120 0.084 0.578# 
Waist (cm) -0.245 0.114 0.184# 0.153 0.332 0.386# 
WHR  -0.302 0.223 0.334# 0.253 0.327 0.405# 
% Body fat 0.167 0.302 0.856# 0.246 0.127 0.291# 
Vis fat (cm²) 0.080 0.794 0.784# -0.246 0.440 0.525# 
Sc fat (cm²) 0.096 0.756 0.783# -0.016 0.960 0.993# 
FPG (mmol/l) -0.166 0.020 0.117 -0.033 0.646 0.944 
FPI (mmol/l) -0.537 7.01x10-5 0.147 -0.098 0.501 0.644 
oGTT 2h (mmol/l) -0.001 0.996 0.620 -0.039 0.886 0.590 
GIR (µmol/kg/min) -0.177 0.581 0.768 0.190 0.554 0.665 
HbA1c (%) 0.125 0.350 0.083 0.073 0.590 0.516 
Chol (mmol/l) 0.024 0.780 0.624 0.068 0.426 0.449 
HDL (mmol/l) 0.142 0.154 0.443 -0.027 0.788 0.958 
LDL (mmol/l) -0.055 0.581 0.888 0.088 0.377 0.355 
TG (mmol/l) -0.021 0.805 0.675 0.044 0.604 0.548 
FFA (mmol/l) -0.195 0.566 0.112 -0.171 0.616 0.266 
Leptin (ng/ml) -0.385 0.103 0.910 -0.427 0.077 0.057 
Adiponectin (µg/ml) 0.066 0.789 0.048 0.304 0.219 0.394 
IL6 (pg/ml) -0.390 0.236 0.133 -0.280 0.434 0.487 
Vis mean (cm²) 0.083 0.582 0.805# 0.000 0.998 0.811# 
Sc mean (cm²) 0.142 0.346 0.601# -0.048 0.752 0.429# 
Vis max (cm²) 0.107 0.478 0.955# -0.005 0.976 0.669# 
Sc max (cm²) 0.209 0.164 0.390# -0.139 0.356 0.275# 
The data are given as mean± standard deviation, p-values are adjusted for sex, age and BMI,# 
p-value adjusted for sex and age, bold p-values indicate statistical significance. 
R- correlation coefficient, AT- adipose tissue, BMI- body mass index, WHR- waist-to-hip ratio, TG- 
triglycerides, IL-6- interleukin 6, HbA1c- glycohemoglobin, oGTT- oral glucose tolerance test, FPG- fasting 
plasma glucose, FPI- fasting plasma insulin, GIR- glucose infusion rate during the steady state of an euglycemic 
hyperinsulinemic clamp, HDL- high density lipoprotein cholesterol, LDL- low density lipoprotein cholesterol , 
FFA- free fatty acids, Sc- subcutaneous, Vis- visceral, Vis mean- mean adipocyte size in visceral adipose tissue, 
Sc mean- mean adipocyte size in subcutaneous adipose tissue, Vis max- maximum adipocyte size in visceral 
adipose tissue, Sc max- maximum adipocyte size in subcutaneous adipose tissue. 
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Moreover, the KLF13 SNP rs8042543 was associated with WHR (p=0.035 adj. sex, age) and 
the reported association with WHR (p=0.044 adj. BMI) was confirmed as well 1. However, 
whereas the ancestral allele C was associated with higher WHR in the study by Shungin et al., 
in my work the C allele was related to lower WHR. This inconsistent effect direction might be 
attributed to the character of study populations, with an obvious tendency towards extreme 
obesity in the present study cohort, which might significantly bias the measurement of WHR. 
Furthermore, I found an association of the T allele with higher maximum size of adipocytes in 
ScAT (p= 0.001) and VAT (p= 0.044) (Table 3). Finally, in a subgroup of individuals with both 
mRNA expression and genotyping data (N=79) I identified a significant association (p=0.042, 
Figure 2) between the KLF13 mRNA expression in ScAT and the SNP. Homozygous carriers 
of the minor allele T showed higher KLF13 mRNA expression level, suggesting rs8042543 
SNP effects the KLF13 gene regulation in ScAT. In databases like RegulomeDB 16, HaploReg 
17 or GTex 18 no eQTL or link to other transcription factors have been reported so far.  
 
Table 3. Association of rs8042543 with metabolic traits 
 
 rs8042543 
Trait CC CT TT adj. p-value 
BMI (kg/m²) 40.9±13.3 41.1±13.6 40.4±15.1 0.704# 
% body fat 42.0±11.9 43.8±11.2 42.5±11.7 0.848# 
Weight (kg) 117.4±39.3 121.1±46.5 114.3±44.9 0.555# 
Waist (cm) 112.3±26.9 118.3±29.7 120.0±35.2 0.084# 
Hip (cm) 126.8±30.5 131.4±30.3 127.4±34.9 0.434# 
WHR 0.88±0.09 0.90±0.08 0.94±0.13 0.035# 
WHRadjBMI    0.044 
FPG (mmol/l) 5.3±0.8 5.2±0.8 5.2±0.8 0.543 
FPI (mmol/l) 82.0±67.9 109.1±75.4 83.5±72.5 0.115 
GIR µmol/kg/min) 93.0±22.1 88.2±24.6 91.0±16.7 0.438 
HbA1c (%) 5.54±0.41 5.46±0.46 5.49±0.52 0.946 
Cholesterol (mmol/l) 4.8±0.9 4.7±1.0 4.7±1.2 0.727 
HDL (mmol/l) 1.3±0.3 1.3±0.4 1.4±0.6 0.608 
LDL (mmol/l) 3.0±0.8 3.0±1.0 2.9±1.0 0.346 
TG (mmol/l) 1.3±0.6 1.2±0.5 1.2±0.6 0.329 
FFA (mmol/l) 0.36±0.32 0.39±0.33 0.52±0.43 0.998 
Leptin (ng/ml) 9.1±4.9 9.2±4.7 8.1±5.5 0.839 
Adiponectin (µg/ml) 36.1±24.7 35.0±18.6 42.9±31.6 0.208 
Vis fat (cm²) 171.5±129.6 195.8±153.2 192.4±171.5 0.409# 
Sc fat (cm²) 1014.0±836.0 1069.8±800.9 1044.7±923.3 0.234# 
lnKLF13 sc 5.5±1.1 5.7±1.3 6.7±0.3 0.042 
lnKLF13 vis 0.5±0.9 0.5±0.4 0.9±0.3 0.947 
Table continued on the next page 
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The data are given as mean ± standard deviation, p-values are adjusted for sex, age and BMI,# 
p-value adjusted for sex and age, bold p-values indicate statistical significance. 
AT- adipose tissue, BMI- body mass index, WHR- waist-to-hip ratio, TG- triglycerides, IL-6- interleukin 6, 
HbA1c- glycohemoglobin, oGTT- oral glucose tolerance test, FPG- fasting plasma glucose, FPI- fasting plasma 
insulin, GIR- glucose infusion rate during the steady state of an euglycemic hyperinsulinemic clamp, HDL- high 
density lipoprotein cholesterol, LDL- low density lipoprotein cholesterol , FFA- free fatty acids, Sc- 
subcutaneous, Vis- visceral, Vis mean- mean adipocyte size in visceral adipose tissue, Sc mean- mean adipocyte 
size in subcutaneous adipose tissue, Vis max- maximum adipocyte size in visceral adipose tissue, Sc max- 
maximum adipocyte size in subcutaneous adipose tissue. 
 
Figure 2. Association of variant rs8042543 with KLF13 expression in human ScAT and VAT. Scatter dot 
plots represent KLF13 mRNA expression in ScAT (A) and VAT (B) grouped by genotype for rs8042543. 
Indicated are p-values of linear regression analysis using the additive model of inheritance and adjusted for sex, 
age and BMI.  
 
5.4.2. Klf13 knockdown affects the mRNA expression of Cebpb and Pparg in adipocytes  
The siRNA mediated knockdown of Klf13 appeared to be more efficient in the epididymal cells 
(downregulated to 25 %) than in the inguinal cells (38 %; Figure 3). In the inguinal cells the 
Klf13 mRNA expression rapidly recovered at day six. In the epididymal cells the Klf13 mRNA 
levels remained lower during the differentiation compared to the non-targeting control (Figure 
3).  
 rs8042543 
Trait CC CT TT adj. p-value 
Vis mean (cm²) 119.1±18.0 117.4±23.3 117.7±16.5 0.596# 
Sc mean (cm²) 122.7±17.1 124.5±20.4 127.0±21.0 0.534# 
Vis max (cm²) 199.9±32.0 218.1±85.6 244.0±111.7 0.044# 
Sc max (cm²) 198.7±46.2 227.0±93.1 259.9±123.1 0.001# 
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Figure 3. The mRNA expression of Klf13 after Klf13-siRNA knockdown during adipogenesis. Relative Klf13 
mRNA expression are plotted against time of differentiation in murine inguinal (A) and epididymal (B) cells. Klf13 
mRNA level was normalized to Hprt1 as a reference gene and is presented relative to gene expression in non-
targeting control cells. 
 
In both fat cell types the control as well as Klf13 siRNA knockdown cells were differentiated 
(Figure 4) and filled with lipids as quantified by AdipoRed/Hoechst (Figure 5). However, 
compared to control cells, Klf13 siRNA treated cells did not differ in the amount of the 
AdipoRed in inguinal or epididymal adipocytes.  
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Figure 4. Microscopy of inguinal and epididymal cells in course of differentiation after transfection with 
siRNA. Epididymal (A-F) and inguinal (G-L) preadipocytes were transfected with Klf13 siRNA (D-F and J-L) 
or for control with non-targeting control siRNA (A-C and G-I). At the day of induction of differentiation (A, D, 
G and J) and at day four (B, E, H and K) bright field pictures were made under the microscope (10 x 
magnification). At day eight lipids were stained with AdipoRed® and fluorescence images were taken (C, F, I 
and L; 10 x magnification, FITC channel; exposure time 1000 ms). 
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Figure 5. AdipoRed signal during the differentiation after transfection with siRNA. Relative fluorescence 
signal of AdipoRed normalized to signal of Hoechst during the differentiation in inguinal (A) and epididymal 
(B) adipocytes. 
 
PPARγ and CEBPβ are transcription factors representing key regulators of the adipogenesis. 
Therefore, I measured the mRNA expression of these genes in Klf13 knockdown and control 
cells. In the inguinal cells the Pparg expression was significantly higher in Klf13 knockdown 
cells compared to the control cells on day zero and day six (Figure 6 A). Albeit not statistically 
significant, also on the other days of differentiation the mRNA levels of Pparg remained higher 
in knockdown cells. In epididymal adipocytes the mRNA expression of Pparg was significantly 
higher in Klf13 knockdown cells compared to control cells at day six (Figure 6 B). The leptin 
mRNA expression showed no differences between treated cells and control cells neither in 
inguinal nor epididymal adipocytes (Figure 7 A-B). The mRNA expression of Cebpb, was 
found to be significantly higher in Klf13 knockdown cells compared to control cells during the 
differentiation in both cell lines (Figure 7 C-D). In porcine adipocytes PPARG has been shown 
to be the target gene of KLF13 11. Accordingly, it was speculated that Pparg is also the target 
gene for Klf13 in murine adipocytes, but based on the present results it seems that contrary to 
the effects on Cebpb mRNA expression, Klf13 knockdown does not influence the Pparg 
expression during murine adipocyte differentiation.  
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Figure 6. The mRNA expression of Pparg after Klf13-siRNA knockdown during the adipogenesis. Relative 
Pparg mRNA expression are plotted against time of differentiation in murine inguinal (A) and epididymal (B) 
cells. Pparg mRNA level was normalized to Hprt1 as a reference gene and is presented relative to gene 
expression in non-targeting control cells. **p<0.01; ***p<0.001 
 
Figure 7 . The mRNA expression of Leptin and Cebpb after Klf13- siRNA knockdown during adipogenesis. 
Relative Leptin and Cebpb mRNA expression are plotted against time of differentiation in murine inguinal (A) 
and epididymal (B) cells. Leptin and Cebpb mRNA level was normalized to Hprt1 as a reference gene and is 
presented relative to gene expression in non-targeting control cells. *** p<0.001 
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5.5. Summary 
In the present study, I measured in paired samples of ScAT and VAT the mRNA expression of 
KLF13 as a plausible candidate gene involved in the regulation of body FD. I show depot 
specific mRNA levels of KLF13 with significantly higher mRNA expression in VAT compared 
to ScAT. Moreover, the subcutaneous KLF13 mRNA levels correlate with weight and BMI. 
Although inconsistent in allele effect direction, I also confirm the reported association of the 
variant rs8042543 with WHR1. Additionally I report a significant association between 
rs8042543 and the maximum size of adipocytes in both ScAT and in VAT. In a subgroup of 
subjects (N=79), the rs8042543 T-allele is significantly associated with a higher mRNA 
expression of KLF13 in ScAT. 
It was shown by Jiang et al. that in porcine adipocytes, KLF13 has an influence on adipogenesis 
through the activation of PPARG 11 . SiRNA mediated knockdown of Klf13 in murine inguinal 
and epididymal preadipocytes in the present study did not result in differences in the AdipoRed 
signal (stain the intracellular lipid droplets). The mRNA expression of Pparg and Cebpb, two 
master regulators of the adipogenesis, were higher in Klf13 knockdown cells compared to 
control cells at some time points of the differentiation.  
In conclusion, this work suggests a relationship between the AT specific expression of KLF13 
and body FD. Although further experiments with isolated human adipocytes are inevitable to 
get more insights into the role of these genes in the regulation of body FD, my findings strongly 
suggest that the link with FD might be mediated by the functional role of KLF13 in 
adipogenesis. 
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Obesity is a growing health problem characterized by a variety of related complications like 
fatty liver disease, T2D and cardiovascular diseases. One of the major organs relevant for 
obesity is the AT, which is not only a passive reservoir for fat. In the last decades it has been 
shown that AT is an endocrine organ located in different sites of the body. The AT is mainly 
distributed in two depots, the ScAT and VAT. It is well acknowledged that fat stored 
prominently in VAT makes subjects more prone for metabolic complications. In the clinical 
practice waist circumference and WHR are common measures of the regional FD but the gold 
standard are the imaging techniques such as CT or whole body MRI scans. It is also known that 
obesity as well as FD are controlled by genetic factors including single nucleotide 
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polymorphisms, deletions or insertions of nucleotides or sequences; but also the altered mRNA 
expression or epigenetic modifications like DNA methylation play a role. There is clear 
evidence that the majority of obesity cases have a polygenic character. This thesis aims to 
identify and characterize novel candidate genes to gain further insights into different types of 
obesity and into causes and consequences of adverse FD, including related comorbidities, which 
are described more in detail in Chapter 1. 
Chapter 2 deals with the first candidate gene of this thesis – the hypoxia inducible factor 3 
subunit alpha (HIF3A). HIF3A was recently shown in an EWAS as a plausible candidate gene 
whose DNA methylation and mRNA expression in ScAT strongly correlated with BMI. In this 
study, I measured the mRNA expression of HIF3A in paired samples of ScAT and VAT and 
correlated these with parameters of obesity and FD. I found higher mRNA levels in ScAT 
compared to VAT, which was true for both AT and isolated adipocytes. I confirmed the 
correlation of HIF3A expression levels with BMI in ScAT and showed for the first time the 
same pattern in VAT. The mRNA expression of HIF3A in both fat depots correlated with 
different parameters of obesity and FD like BMI, waist and WHR. In subgroups of individuals 
I investigated the effects of reported HIF3A genetic variants on its mRNA expression in AT 
and methylation on reported CpG-sites (cg22891017). The methylation levels in VAT 
correlated with hip, subcutaneous fat mass, CT ratio and adiponectin levels. For the investigated 
cohort I found higher HIF3A methylation levels in VAT compared to ScAT, which is in 
accordance with mRNA expression that was found to be lower in VAT compared to ScAT. 
Therefore, a regulation of gene expression through DNA methylation could be hypothesized. 
The HIF3A variant rs8102595 was associated with the methylation levels in ScAT as reported 
by Dick et al., but I also observed a significant association between the variant and the 
methylation levels in VAT. Furthermore, I showed significant associations of the variant with 
HDL, glucose infiltration rate and maximum fat cell size of ScAT. For the second reported 
variant rs3826795 I suggest its effects on the methylation level, but also on the total cholesterol 
and the mean fat cell size of VAT.  
In conclusion, my data not only support previously reported results, but also reveal that the 
mRNA expression and the methylation level of HIF3A cg22891017 are fat depot specific and 
related to obesity and AT dysfunction. In the meantime, other groups have replicated my results 
in their studies, thus demonstrating that HIF3A is an attractive candidate involved in the 
regulation of AT function, and is potentially providing a link to metabolic complications of 
obesity and FD. 
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GWAS/EWAS became possible with the development of high-throughput DNA/RNA 
technologies as an approach to identify new candidate loci. In 1998 Kovacs et al. identified a 
QTL for serum fasting insulin, TG and body weight in rats on chromosome 4, which carries the 
zinc finger protein replication initiator 1 (REPIN1) gene. In the coming years different analyses 
in mice and rats showed that Repin1 influences the lipid and glucose metabolism and turns out 
to be a candidate gene for obesity and related complications. In my study, presented in Chapter 
3, I showed for the first time a strong relationship between genetic variants in REPIN1 with 
metabolic traits in humans. REPIN1 was sequenced (four exons, exon-intron boundaries, 5´ and 
3´ UTRs) in 48 unrelated Caucasian subjects and the detected variants were summarized in 
eight L.D. groups. Additionally, a 12 bp deletion was found in exon 4. Eight so called tagging 
variants representing the L.D. groups and the 12 bp deletion were analyzed in two independent 
cohorts (Leipzig cohort and Sorb cohort). I found associations with traits related to obesity and 
glucose metabolism (e.g., total and low density lipoprotein cholesterol, serum TG, glucose 
infiltration rate and HbA1c). The 12 bp deletion (rs3832490) is very rare, so that only 
heterozygote carriers were detected in the Leipzig cohort. The genotype-phenotype analyses 
revealed nominal associations with % body fat, 120 minute plasma glucose levels and the 
maximums size of adipocytes in VAT and ScAT. In a second independent cohort, only three 
homozygous carriers of the 12 bp deletion have been identified and they had lower fasting 
plasma glucose and HOMA B, which is consistent with the lower risk for T2D, which was 
observed in a case-control study. These three subjects also had a lower BMI, WHR, % body fat 
and serum TG but on the other hand they had higher HDL, LDL and total cholesterol levels. 
Based on these interesting findings we investigated the 12 bp deletion in HepG2 cells. The 
HepG2 cells were transfected with plasmids carrying the REPIN1 sequence with or without the 
12 bps and we analyzed the glucose and lipid metabolism. We showed that cells transfected 
with the REPIN1 12 bp deletion had more lipid droplets and an higher mRNA expression of 
transcription factors such as peroxisome proliferator activated receptor α (PPARA), PPARG-
Isoform 2 and sterol regulatory element binding protein 1c (SREBP-1c) as compared to the 
wildtype transfected cells. Furthermore, HepG2 cells transfected with this REPIN1 variant also 
had significantly higher mRNA expression levels for fatty acid transport protein 4 (FATP4) 
and CD36, whereas apolipoprotein M (APOM ) was significantly downregulated in these cells 
and the glycerol levels were twice as high as in the wildtype transfected cells. Further, the 
glucose transporters were influenced by the 12 bp deletion so that the mRNA expression of 
glucose transporter protein 2 (GLUT2) was higher and more GLUT2 positive cells were 
observed in this case. These findings suggest that genetic variation in REPIN1, especially the 
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12 bp deletion (rs3832490), may contribute to changes in parameters of glucose and lipid 
metabolism, most likely due to specific REPIN1 genotype related regulation of target gene 
expression in glucose metabolism, insulin sensitivity, fatty acid transport and adipogenesis. 
Dissecting the causal gene(s)/variant(s) in loci shown to be associated with diseases or complex 
traits remains a major challenge. In the last decade, the FTO locus has been studied extensively, 
however the molecular mechanisms underlying the reported associations are still not fully 
understood. Recent studies suggest that the BMI-associated variants in FTO not only affect the 
FTO itself, but also the nearby genes like iroquios homeobox 3 (IRX3) and IRX5. Therefore, I 
measured the mRNA expression of IRX3 and IRX5 in paired samples of VAT and ScAT and 
correlated these with parameters related to obesity and lipid and glucose metabolism. The 
results are summarized in Chapter 4. Although I did not find fat depot specific mRNA 
expression for IRX3, the mRNA expression of IRX5 was significantly higher in ScAT compared 
to VAT. Moreover, the subcutaneous mRNA levels of IRX3 were significantly correlated with 
weight and BMI. The correlation with waist, leptin and interleukin 6 levels, however, did not 
withstand adjustments for sex, age and BMI. The visceral mRNA expression of IRX3 correlated 
with weight, BMI and waist, and the visceral IRX5 mRNA expression correlated with weight, 
BMI, waist, % body fat and fasting plasma glucose. However, none of these correlations 
withstood the adjustments for adequate covariates. The obesity SNP rs8050136 at FTO was 
associated with weight, waist and hip, but no significant association with the mRNA expression 
of IRX3 and IRX5 was observed. In summary, my data demonstrated for the first time 
associations of IRX3 with obesity related traits as well as a depot specific mRNA expression of 
IRX5, thus supporting the role of these genes in the pathophysiology of obesity. 
Multiple GWAS uncovered a number of loci, which are associated with WHR. One of them, 
KLF13, was analyzed as described in Chapter 5. The KLF13 mRNA expression was higher in 
VAT compared to ScAT. The mRNA expression in both AT correlated significantly with age 
and additionally the KLF13 levels in ScAT correlated with weight and BMI. I confirmed the 
reported association between rs8042543 and WHR and showed that carriers with the minor 
allele T had higher maximum size of adipocytes in ScAT and VAT and correlated with higher 
mRNA expression of KLF13 in ScAT as well. In further cell culture experiments I transfected 
inguinal and epididymal preadipocytes with Klf13 siRNA and NTC siRNA as control and 
differentiated these to adipocytes. The Klf13 knockdown cells showed no significantly different 
AdipoRed signal compared to control cells. However, at specific timepoints during the 
differentiation of the preadipocytes, there were significantly higher mRNA expression of Pparg 
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and Cebpb in Klf13 siRNA treated cells, which are the main regulators of the adipogenesis, 
suggesting the role of Klf13 in the adipogenesis.  
In summary, the above mentioned studies added successfully further pieces to the puzzle of 
polygenic obesity, contributing to better understanding of the role of genetic and epigenetic 
factors involved in FD distribution and of the link between obesity and its metabolic sequelae. 
I demonstrated that various approaches can be employed to identify novel candidate genes for 
FD and obesity. The elucidation of the involved pathways and processes is now the next big 
challenge, which was also addressed in my studies. HIF3A was initially identified in an EWAS 
for the trait BMI and my data suggested that this gene is involved in AT dysfunction via 
epigenetic regulation of its expression. For REPIN1, identified in a QTL analysis, I showed that 
its genetic variation has an impact on glucose and lipid metabolism, which in turn seems to 
influence Repin1 itself. However, as I showed in my study on IRX3 and IRX5 not only genes 
within the next proximity of the associated genetic variants but also structurally adjacent genes 
need to be considered for elucidation of causality behind the observed associations. Also 
reported loci from GWAS can be possible candidate genes and can help to find the link between 
AT dysfunction and adipogenesis as I showed in my study on KLF13. 
Despite recent advances in our understanding of the obesity genetics, it is evident that many big 
challenges are yet to come in near future. For instance, we will need to understand how genes 
interact between each other as well as with the environment, which can ultimately shape the 
genes impact on a specific trait or disease. Better knowledge of mechanisms underlying or 
mediating gene-environment interaction will be essential to pave the road to the precision 
medicine, i.e. to tailor medical treatment to the individual characteristics of each patient.
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